Da	te: <u>Oct. 19<sup>th</sup>, 2021</u>			
Yo	ur Name: <u>Koic</u>	hiro Nozaki		
Ma	nuscript Title: Effectiveness	of afatinib in an NSCLC p	atient with EGFR mutation and early progression to Osi	<u>imertinib.</u>
Ma	nuscript number (if known)	): <u>TCR-21</u>	-1850	
rela par to	ated to the content of your ties whose interests may b	manuscript. "Related" me e affected by the content necessarily indicate a bias	Il relationships/activities/interests listed below that are eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment . If you are in doubt about whether to list a o so.	
	e following questions apply nuscript only.	to the author's relationsh	ips/activities/interests as they relate to the <u>current</u>	
to		ension, you should declar	edefined broadly. For example, if your manuscript pertale all relationships with manufacturers of antihypertensithe manuscript.	
	tem #1 below, report all su time frame for disclosure i		ed in this manuscript without time limit. For all other it	ems,
		Name all entities with	Specifications/Comments	
		whom you have this	(e.g., if payments were made to you or to your	
		relationship or indicate	institution)	
		none (add rows as		
		needed)		
		Time frame: Since the initia	al planning of the work	
L	All support for the present manuscript (e.g., funding,	XNone		
	provision of study materials,			
	medical writing, article			
	processing charges, etc.)			
	No time limit for this item.			
		Time frame: pas	t 36 months	
2	Grants or contracts from	XNone		

any entity (if not indicated

X\_\_None

\_X\_\_None

in item #1 above).
Royalties or licenses

Consulting fees

4

5	Payment or honoraria for	AstraZeneca	honoraria for lectures
	lectures, presentations,	Boehringer Ingelheim	honoraria for lectures
	speakers bureaus,	MSD	honoraria for lectures
	manuscript writing or educational events	Taiho Pharmaceutical	honoraria for lectures
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	XNone	
	financial interests		
		•	

The author receives honoraria for lectures from AstraZeneca, Boehringer Ingelheim, Taiho Pharmaceutical and MSD.

# Please place an "X" next to the following statement to indicate your agreement:

\_\_X\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: _	Oct. 19 <sup>th</sup> , 2021		
Your N	ame: <u>Satoshi Watanabe</u>		
Manus	cript Title: <u>Effectiveness o</u>	f afatinib in an NSCLC patient with	EGFR mutation and early progression to
<u>Osimer</u>	tinib.		
Manus	cript number (if known): _	TCR-21-1850	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
	·	Time trainer since the initial	Statisting of the Work
1	All support for the present	XNone	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

			T
5	Payment or honoraria for	AstraZeneca	
,	lectures, presentations,	Chugai Pharma	
	speakers bureaus,	Boehringer Ingelheim	
	manuscript writing or	Ono Pharmaceutical	-
	educational events	Bristol-Myers	-
		Eli Lilly	-
		MSD	-
		Taiho Pharmaceutical	
		Pfizer	1
		Novartis	
		Daiichi Sankyo	
6	Payment for expert	XNone	
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	X None	
	pending		
9	Douticipation on a Data	V. None	
9	Participation on a Data Safety Monitoring Board or	XNone	
	Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,	XNotie	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
11	Stock of Stock options	^NOTIC	
12	Possint of agricument	V None	
12	Receipt of equipment, materials, drugs, medical	X_None	
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		

The author receives honoraria for lectures from AstraZeneca, Chugai Pharma, Ono Pharmaceutical, Bristol-Myers, Boehringer Ingelheim, Eli Lilly, MSD, Taiho Pharmaceutical, Pfizer, Novartis and Daiichi Sankyo.

Please place an "X" next to the following statement to indicate your agreement:			
X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.			

Date: <u>Oct. 19<sup>th</sup>, 2021</u>
Your Name: <u>Kazuto Nishio</u>
Manuscript Title: Effectiveness of afatinib in an NSCLC patient with EGFR mutation and early progression to Osimertinib
Manuscript number (if known):TCR-21-1850

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present	X None	planning of the work
1	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	West Japan Oncology	
	any entity (if not indicated	Group	
	in item #1 above).	Ignyta,Inc.	
		Eli Lilly	
		Nippon Boehringer	
		Ingelheim	
		Korea Otsuka	
		Pharmaceutical	
		Thoracic Oncology	
		Research Group	
		North East Japan Study	
		Group	

		Clinical Bassach Communic	
		Clinical Research Support	
		Center Kyushu	
		Nichirei Biosciences Inc.	
_		Osakaminami hospital	
3	Royalties or licenses	<u>X</u> None	
4	Consulting fees	Solasia Pharma	
		Otsuka Pharmaceutical	
		ELI LILLY JAPAN	
		SymBio Pharmaceuticals	
5	Payment or honoraria for	Boehringer Ingelheim	honoraria for lectures
	lectures, presentations,	Japan	
	speakers bureaus,	Chugai	honoraria for lectures
	manuscript writing or	Eisai	honoraria for lectures
	educational events	Pfizer	honoraria for lectures
		Novartis Pharma	honoraria for lectures
		MSD	honoraria for lectures
		ONO PHARMACEUTICAL	honoraria for lectures
		Bristol-Myers Squibb	honoraria for lectures
		Life Technologies Japan	honoraria for lectures
		Yakult Honsha	honoraria for lectures
		Roche Diagnostics	honoraria for lectures
		AstraZeneca	honoraria for lectures
		Sanofi	honoraria for lectures
		Guardant Health	honoraria for lectures
		Amgen	honoraria for lectures
		Merck Biopharma	honoraria for lectures
6	Payment for expert	_X None	
	testimony	-	
	,		
7	Support for attending	_X None	
	meetings and/or travel		
	, , , , , , , , , , , , , , , , , , , ,		
_			
8	Patents planned, issued or	_X None	
	pending		
9	Participation on a Data	<u>X</u> None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	X None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	

1	2 Receipt of equipment,	X None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
1	Other financial or non-	X None	
	financial interests		

The author received lecture fees from CHUGAI PHARMACEUTICAL CO.,LTD., Eisai Co., Ltd., Pfizer Inc., Nippon Boehringer Ingelheim Co., Ltd., Novartis Pharma K.K., MSD K.K., ONO PHARMACEUTICAL CO., LTD., Bristol-Myers Squibb Company, SymBio Pharmaceuticals Limited., Life Technologies Japan Ltd., Solasia Pharma K.K., Eli Lilly Japan K.K., Yakult Honsha Co., Ltd., Roche Diagnostics K.K., Life Technologies Japan Ltd., AstraZeneca K.K., Otsuka Pharmaceutical Co., Ltd., Sanofi K.K., Guardant Health Inc.

Please place an "X" next to the following statement to indicate your agreement:

 $\underline{X}$  I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: <u>Oct. 19<sup>th</sup>, 2021</u>		
Your Name: <u>Kazuko Sakai</u>		
Manuscript Title: <u>Effectiveness o</u>	f afatinib in an NSCLC patient with EGFR mutation and early progression to Osime	ertinib.
Manuscript number (if known):_	TCR-21-1850	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	planning of the work
1	All support for the present manuscript (e.g., funding,	XNone	
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	<u>X None</u>	
4	Consulting fees	X None	
5	Payment or honoraria for	Roche Diagnostics	honoraria for lectures
	lectures, presentations,	Bio-Rad	honoraria for lectures

	speakers bureaus,	AstraZeneca	honoraria for lectures
	manuscript writing or	Chugai Pharmaceutical	honoraria for lectures
	educational events	Hitachi	honoraria for lectures
6	Payment for expert	<u>X</u> None	
	testimony		
7	Support for attending	X None	
	meetings and/or travel		
8	Patents planned, issued or	X None	
	pending		
9	Participation on a Data	X None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	X None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	<u>X</u> None	
4.5			
12	Receipt of equipment,	<u>X</u> None	
	materials, drugs, medical		
	writing, gifts or other services		
12	Other financial or non-	V Nana	
13	financial interests	<u>X</u> None	
	illiancial iliterests		

The author receives honoraria for lectures from Roche Diagnostics, Bio-Rad, AstraZeneca, Chugai Pharmaceutical, and Hitachi.

# Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: _	Oct. 19	<sup>th</sup> , 2021
Your N	lame:	Toshiaki Kikuchi
Manus	cript Title	: Effectiveness of afatinib in an NSCLC patient with EGFR mutation and early progression to Osimertinib
Manus	cript num	ber (if known): TCR-21-1850
In the	interest of	transparency, we ask you to disclose all relationships/activities/interests listed below that are

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)  planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
2	Grants or contracts from any entity (if not indicated in item #1 above).  Royalties or licenses	AstraZeneca K.K. Nippon Boehringer Ingelheim Co., Ltd  X None	36 months
4	Consulting fees	XNone	

5	Payment or honoraria for lectures, presentations,	Nippon Boehringer Ingelheim Co., Ltd	
	speakers bureaus, manuscript writing or	AstraZeneca K.K.	
	educational events		
6	Payment for expert testimony	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	XNone	
	periamg		
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role	X None	
	in other board, society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X None	
13	Other financial or non- financial interests	XNone	

The author receives grants from Nippon Boehringer Ingelheim Co., Ltd and AstraZeneca K.K., and honoraria for lectures from Nippon Boehringer Ingelheim Co., Ltd and AstraZeneca K.K.

Please place an "X" next to the following statement to indicate your agreement:

\_\_X\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.